Compounded Semaglutide vs. Brand-Name Ozempic: What Is the Actual Difference?

The active molecule in compounded semaglutide and brand-name Ozempic is semaglutide. Both should, at their best, deliver the same molecule in the same concentration to the same receptor. The difference is in everything surrounding the molecule: how it was manufactured, by whom, under what oversight, and how you know what you are actually getting.

That distinction has grown more important as compounded semaglutide has become a major industry.

What Compounding Actually Means

Pharmaceutical compounding is the preparation of a customized medication for a specific patient, mixing, combining, or altering ingredients to create a drug that is not commercially available or that a patient cannot tolerate in its standard form. A pharmacist might compound a liquid version of a drug for someone who cannot swallow pills, or create a combination product not available commercially.

Two regulatory categories of compounding pharmacies exist in the United States, and the distinction matters for semaglutide in practical terms.

503A pharmacies are traditional compounding pharmacies regulated primarily by state boards of pharmacy. They compound medications in response to individual patient prescriptions, are prohibited from anticipatory compounding (making batches in advance without a specific patient), and are not subject to FDA manufacturing standards (Current Good Manufacturing Practice, or cGMP). Their products cannot be sold across state lines.

503B outsourcing facilities operate under FDA oversight and must meet cGMP standards, the same manufacturing quality standards that govern brand-name pharmaceutical manufacturers. They can produce larger batches and distribute across state lines, but they are still compounding facilities, not drug manufacturers. Their quality standards are meaningfully higher than 503A pharmacies.

During the period of official semaglutide shortage, both 503A and 503B facilities were legally permitted to compound semaglutide under FDA shortage exemptions.

The Shortage Period and Its End

The FDA’s drug shortage database listed semaglutide injection in shortage from 2022 through early 2025, driven by demand dramatically outpacing Novo Nordisk’s manufacturing capacity. During this shortage period, compounding was legally permitted under specific FDA guidance.

In early 2025, the FDA determined that the shortage of Wegovy (semaglutide 2.4 mg for weight management) had resolved, and notified compounders that they would need to wind down production. 503A pharmacies faced an immediate requirement to stop mass compounding. 503B outsourcing facilities were given a short transition window.

This created a complex legal situation. Some compounders continued operations arguing their products were sufficiently different from brand-name semaglutide, for instance by adding ingredients like B12 or amino acids, to remain outside the shortage exemption’s scope. The FDA has challenged some of these claims, and litigation is ongoing.

The practical result for consumers is that the legality and quality of any specific compounded semaglutide product now depends heavily on when and where it was made, and whether the compounding facility is operating within current FDA guidance.

What “Compounded” Does Not Mean

Compounded semaglutide is not counterfeit semaglutide. Counterfeiting involves making a product designed to look like a brand-name product without authorization. Compounding involves making a pharmaceutical preparation from ingredients.

That said, not all compounding is equal. The raw semaglutide used by compounders comes from active pharmaceutical ingredient (API) suppliers, many of them overseas. The quality of these APIs varies. A 503B outsourcing facility operating under cGMP with third-party testing of its API is in a fundamentally different position than a 503A pharmacy ordering API from a supplier it has not independently verified.

Some products sold as compounded semaglutide use semaglutide acetate or semaglutide sodium rather than the base form. The FDA has stated that these salt forms are not FDA-approved for use in compounding and that insufficient evidence of safety or effectiveness exists for the salt forms versus the base molecule. This is an active area of regulatory concern.

How to Verify Before Purchasing

If you are considering compounded semaglutide, several verification steps are worth taking.

State pharmacy license: Check that the compounding pharmacy is licensed in your state. State pharmacy boards maintain online license lookup tools. An unlicensed pharmacy is a hard stop.

503B registration: If the pharmacy claims to be an FDA-registered 503B outsourcing facility, verify it on the FDA’s outsourcing facility database. The list is public and searchable.

LegitScript certification: LegitScript is an independent certification organization that verifies online pharmacies and telehealth providers against legal and safety standards. Their certification does not guarantee product quality but indicates the business has passed basic legitimacy checks. Their database is publicly searchable at legitscript.com.

Third-party testing: Reputable 503B facilities can provide certificates of analysis (CoA) for their batches, showing testing results for purity, sterility, and concentration. Ask whether these are available. A facility that cannot or will not provide CoAs should raise questions.

The prescribing provider: A telehealth provider ordering compounded semaglutide from a specific pharmacy partnership should be able to tell you which facility manufactures the product and what their quality verification process is. A provider who cannot answer basic questions about where the medication comes from is worth reconsidering.

Brand-Name: What You Actually Pay For

Ozempic and Wegovy from Novo Nordisk are manufactured at pharmaceutical-grade facilities, subject to full FDA cGMP oversight, and contain semaglutide that has been tested, approved, and manufactured at scale with documented quality controls. You know exactly what you are getting and at what concentration.

The tradeoffs are cost and availability. Brand-name Wegovy lists at over $1,300 per month without insurance. With GLP-1 coverage, which many insurers and employers have restricted, out-of-pocket cost can still be significant. Compounded versions often run $200-400 per month.

Whether the cost difference is worth the regulatory certainty depends on what the compounded product’s provenance actually is. A verified 503B product with documented API sourcing and batch testing is meaningfully different from a product that cannot answer basic questions about where it came from.

The gray area is real. The answer is verifying rather than assuming.

For context on how to evaluate online weight loss programs that prescribe semaglutide, see How to Get Weight Loss Medication Online: What You Need to Know Before You Sign Up. For the underlying mechanism of how semaglutide works, see What Is Semaglutide and How Does It Work for Weight Loss?